Any systemic treatment vs placebo
Tofacitinib · people with chronic plaque psoriasis
Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty).
2 findings from 1 review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes onlyRR 8.19 [6.53, 10.29]5 studies · 3092 participantsLow
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes onlyRR 1.01 [0.57, 1.77]7 studies · 3122 participantsModerate